Compare Novartis AG (NVS) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs US Bancorp — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while US Bancorp trades at $57.18 (market cap $87.52B). The key difference: Novartis AG is far larger — about 3.1× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.85%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and US Bancorp for 97 Days on average.
| NVS | USB | |
|---|---|---|
Market Cap | $274.00B | $87.52B |
Volume | 1,852,137 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $168.62 | $65.42 |
52-Week Low | $121.80 | $45.28 |
Typical Hold Time | 82 Days | 97 Days |
Enterprise Value | $315.32B | $117.01B |
Dividend Yield | 3.31% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
U.S. Bancorp (USB) trades at $57.03, down 0.45% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.35 exceeding expectations by 5.5%. Revenue growth accelerated to $28.54B in 2025 with net income margin improving to 27.61%. Analyst consensus remains positive with 51% buy ratings and $69.94 price target representing 23% upside potential.
USB presents a value opportunity with attractive valuation multiples (P/E 11.21, P/B 1.44) and dividend yield of 3.8%. Near-term risks include technical weakness and regulatory uncertainties, but strong fee revenue growth and capital markets performance support the bullish fundamental case. The stock offers income appeal with sustainable dividend growth and clean loan portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
